CN Patent

CN116082259B — 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂

Assigned to Beijing Ruipuxin Biotechnology Co ltd · Expires 2024-04-02 · 2y expired

What this patent protects

本申请公开了氨基甲酸酯基或氨甲酰基取代的5‑HT2B拮抗剂化合物，已经发现所述化合物由于氨基甲酸酯基或氨甲酰基的取代，特别是氨基甲酸酯基的取代而与5‑HT2B受体的结合活性增加，和使用所述化合物治疗或预防由5‑HT2B介导的障碍的方法。

USPTO Abstract

本申请公开了氨基甲酸酯基或氨甲酰基取代的5‑HT2B拮抗剂化合物，已经发现所述化合物由于氨基甲酸酯基或氨甲酰基的取代，特别是氨基甲酸酯基的取代而与5‑HT2B受体的结合活性增加，和使用所述化合物治疗或预防由5‑HT2B介导的障碍的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116082259B
Jurisdiction
CN
Classification
—
Expires
2024-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Ruipuxin Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.